Therapeutics News and Research

RSS

Chelsea prices common stock public offering

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.

1 Oct 2010

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

The National Institute of General Medical Sciences (NIGMS) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $30 million grant to study the structure and function of thousands of biomedically important proteins.

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Repros Therapeutics Inc. today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

30 Sep 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Warburg Pincus to invest CDN $35 million in Protox

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.

30 Sep 2010

Tryton reports positive interim results from Side Branch Stent System study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced interim six-month results from a symposium during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.

30 Sep 2010

Tobira completes $31 million Series B financing

Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, today announced the completion of a $31 million Series B financing. New investor Novo A/S is leading the round, joined by original investors, Domain Associates, L.L.C., Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

30 Sep 2010

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

An $18 million research program headed by Washington University School of Medicine in St. Louis will research therapies and diagnostic tools for heart and lung diseases that use nanotechnology.

30 Sep 2010

New form of immunotherapy increases survival in children with neuroblastoma

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.

30 Sep 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

The Center of Excellence (COE) on Brain Aging at NYU Langone Medical Center has established a specialty center for the diagnosis and treatment of Lewy Body Disease, a multi-system disease involving disturbances of cognition, behavior, sleep and autonomic function. Lewy Body Disease, or LBD, affects an estimated 1.3 million individuals in the United States and is widely misdiagnosed because LBD symptoms closely resemble those of other more commonly known diseases such as Alzheimer's and Parkinson's disease.

30 Sep 2010

Researchers receive NIH award to investigate regenerative potential of retinal cells

Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.

30 Sep 2010

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

30 Sep 2010

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).

30 Sep 2010

Breakthrough neuroblastoma treatment

According to a new study the addition of an experimental immunotherapy drug to the standard regimen of care extended the lives and decreased the risk of a disease recurrence in children with high-risk neuroblastoma. This tumor most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. It forms 12 percent of cancer-related deaths in children under the age of 15 and half of patients with this type of malignancy have the high-risk form.

29 Sep 2010

NeurAxon closes convertible debenture financing

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.

29 Sep 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

Therapeutics News and Research

Chelsea prices common stock public offering

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Cardium expands wound healing and tissue regeneration portfolio

Warburg Pincus to invest CDN $35 million in Protox

Tryton reports positive interim results from Side Branch Stent System study

Tobira completes $31 million Series B financing

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

New form of immunotherapy increases survival in children with neuroblastoma

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

Researchers receive NIH award to investigate regenerative potential of retinal cells

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Breakthrough neuroblastoma treatment

NeurAxon closes convertible debenture financing

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News